IBA (Ion Beam Applications S.A.) has signed a multi-site agreement with Shreeji Imaging and Diagnostic Centre Pvt. Ltd. for the delivery and installation of four Cyclone KIUBE 300 cyclotrons in India. The systems will be deployed in Ahmedabad, Nagpur, Kochi and Bhubaneswar to support the production of fluorine-18 (F-18) for positron emission tomography (PET) radiopharmaceuticals.
The contract is valued at EUR 5–7 million and covers mid-energy cyclotrons intended for the industrial-scale production of F-18 labelled compounds and other PET radiopharmaceuticals. The additional systems are expected to strengthen domestic manufacturing capacity as PET imaging access expands beyond major metropolitan areas.
India’s PET imaging market is expanding as services extend to additional cities, increasing the need for secure tracer supply. Shreeji is adding four Cyclone KIUBE 300 cyclotrons to its existing manufacturing network to bring F-18 production closer to treatment centres and reduce logistics risks, while also creating capacity for new tracers.
“At IBA, we are committed to having a positive societal impact everywhere in the world by enhancing access to cutting-edge care, and we are proud to advance that mission through this contract with Shreeji,” said Charles Kumps, President of IBA RadioPharma Solutions. “India’s nuclear medicine community is growing fast, and reliable, local manufacturing is fundamental to patient access. Partnering with Shreeji to deploy multiple Cyclone KIUBE systems creates a resilient, multi-node network that supports the next phase of PET growth in India while improving consistency of supply for clinicians and their patients.”
Shreeji selected the Cyclone KIUBE platform for its beam current capability, industrial reliability and upgrade pathway that supports evolving tracer portfolios. The systems are designed to enable sustained, Good Manufacturing Practice (GMP)-compliant F-18 production while maintaining operating efficiency across multiple sites.
“IBA’s Cyclone KIUBE gives us the capacity and flexibility we need to serve more centers, more reliably,” said Amit Maniar, Director, Shreeji. “With four new systems coming online, we are significantly boosting domestic production, strengthening supply-chain resilience, and accelerating our ability to introduce next-generation tracers that enhance patient care. We expect this expansion to stimulate latent PET demand by ensuring cost-effective, dependable access to the full spectrum of F-18 isotopes and emerging novel isotopes. It also positions us to support the next wave of healthcare growth across emerging hubs, while adding important redundancy to our network to ensure consistent, nationwide service.”
IBA, based in Louvain-la-Neuve, Belgium, supplies particle accelerator technology for proton therapy, industrial sterilisation, radiopharmaceuticals and dosimetry, and employs approximately 2,100 people worldwide. Shreeji, founded in 2000, operates four GMP-ready cyclotron facilities in Mumbai, Delhi NCR, Lucknow and Bengaluru and supplies PET tracers to more than 300 hospitals and clinics, with additional distribution to Sri Lanka, Nepal and the Maldives.
